TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Implementing FLOW

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* This study uses site-level randomization~* Sites must be VA sites with substantial numbers of mental health patients~  * VA medical centers or large or very large community based outpatient clinics~Exclusion Criteria:~* Non-VA sites and CBOCs smaller than large

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLOW intervention (Type: EXPERIMENTAL): Sites receive the FLOW program, including internal and external facilitation, use of the FLOW online report to identify patients, patient and provider education materials, a medical record template, and regular data tracking and feedback about the process.
- Waitlist until Time 2 (Type: NO_INTERVENTION): Arm 2: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 2.
- Waitlist until Time 3 (Type: NO_INTERVENTION): Arm 3: In this stepped wedge design, sites will be randomized to receive the FLOW intervention at Time 1, or to be in a waitlist until Time 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Primaquine for Clearance of Gametocytes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 2 years and \<15 years~2. Weight over 10kg~3. P. falciparum parasitaemia \>1,000 parasites and \<200,000 parasites/µl~4. P. falciparum gametocytes detected by microscopy~5. Normal G6PD enzyme function~6. Informed consent by legally acceptable representative~Exclusion Criteria:~1. Enrolled in another study~2. Fever or history of fever in the last 24 hours~3. Evidence of severe illness/ danger signs~4. Known allergy to study medications~5. Hb \< 8g/dL~6. Started menstruation~7. Pregnancy or breastfeeding~8. Antimalarials taken within the last 2 days~9. Primaquine taken within the last 4 weeks~10. Blood transfusion within the last 90 days~11. Non-falciparum malaria co-infection

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Artemether-Lumefantrine (Type: ACTIVE_COMPARATOR): Artemether-Lumefantrine combination
- Artemether-Lumefantrine-Primaquine 0.25 (Type: EXPERIMENTAL): Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
- Artemether-Lumefantrine-Primaquine 0.4 (Type: EXPERIMENTAL): Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MOVIPREP® Versus PICOLAX® Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent obtained prior to inclusion~* male or female, aged 18 to 80 years, inclusive, scheduled to undergo a complete colonoscopy~* willing, able and competent to complete the entire procedure and to comply with study instructions~* females of childbearing potential must employ an adequate method of contraception~* if an adequate method of contraception is not being used, the patient will be post hysterectomy, post bilateral oophorectomy, post menopause or have any other condition which precludes pregnancy~* females of childbearing potential must undergo a pregnancy test~Exclusion Criteria:~* ileus~* gastro-intestinal obstruction or perforation~* toxic megacolon, toxic colitis~* congestive heart failure (New York Heart Association \[NYHA\] III + IV)~* acute life-threatening cardiovascular disease~* acute surgical abdominal conditions~* untreated or uncontrolled arterial hypertension~* known clinically significant reduced renal function with creatinine \> 170 µmol/L~* known clinically significant reduced liver function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MOVIPREP
- 2 (Type: ACTIVE_COMPARATOR): Picolax

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Family Model of Diabetes Self-Management Education in the Marshallese Community

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Primary Participant:~* Must be 18 years or older~* Self-reported Diabetes Mellitus Type 2 diagnosis by a health care provider~* Self-reported Marshallese ethnicity or descent~Secondary (Family) Participant:~* Must be 18 years or older~Exclusion Criteria:~* Younger than 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard DSME (Type: ACTIVE_COMPARATOR): Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
- Adapted DSME (Type: EXPERIMENTAL): Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Successful completion of study protocol 3104001~* Response or stable disease in study 3104001 at week 12~Exclusion Criteria:~* New serious concurrent medical condition~* Not able to swallow the study drug

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ODM-201 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Doxycycline Treatment in EM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* solitary erythema migrans~Exclusion Criteria:~* pregnancy or lactation~* immunocompromised~* serious adverse event to doxycycline~* taking antibiotic with antiborrelial activity within 10 days~* multiple erythema migrans or extracutaneous manifestations of lyme borreliosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- EM-7 days doxycycline (Type: ACTIVE_COMPARATOR): None
- EM-14 days doxycycline (Type: ACTIVE_COMPARATOR): None
- Controls (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 2% and no more than 12% affected body surface area.~* Subject has an Investigator's Global Assessment (IGA) score of at least three (moderate) at study start.~* If subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study.~Exclusion Criteria:~* Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.~* Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.~* Subject has used any phototherapy (including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days prior to study start.~* Subject has used any systemic methotrexate, retinoids, systemic corticosteroids \[including intralesional, intra-articular, and intramuscular corticosteroids\], cyclosporine or analogous products within 90 days prior to study start.~* Subject has used any systemic biologic therapy (i.e., FDA-approved or experimental therapy) within five half-lives of the biologic prior to study start.~* Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start or is intending to have such exposure during the study.~* Subject has used topical body (excluding the scalp) psoriasis therapy (including coal tar, anthralin, steroids, retinoids, vitamin D analogs) within 14 days prior to study start.~* Subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at study start.~* Subject is currently using lithium or Plaquenil (hydroxychloroquine).~* Subject is currently using a beta-blocking medication (e.g., propanolol) or angiotensin converting enzyme (ACE) inhibitor at a dose that has not been stabilized.~* Subject is pregnant, lactating, or is planning to become pregnant during the study.~* Subject is currently enrolled in an investigational drug or device study.~* Subject has used an investigational drug or investigational device treatment within 30 days prior to study start.~* Subject has been previously enrolled in this study and treated with a test article.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Arm (Type: EXPERIMENTAL): Topical lotion, applied twice daily
- Vehicle Arm (Type: PLACEBO_COMPARATOR): Topical lotion, applied twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is obese with a body mass index (BMI) \>=30 kg/m\^2 to \<=50 kg/m\^2, and has been obese for at least one year before screening.~* Usually consumes at least three major meals (morning, midday, and evening) each day.~Exclusion Criteria:~* Is currently enrolled in a formal weight-loss program.~* Has had liposuction within 1 year before screening or is planning to have liposuction during the study.~* Has received any investigational drug within 3 months before screening.~* Has previously participated in a study using pramlintide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pramlintide Acetate (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PECS-2 for Breast Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Unilateral surgery on the breast because of suspected malign disease.~Exclusion Criteria:~Bilateral surgery~Metastases other than in the axilla~Body Mass Index (BMI) \> 35~Not able to communicate in Swedish~Dementia~American Society of Anesthesiology (ASA) 4 or 5~Chronic pain treatment (use of opiates or medicine for neuropathic pain \> 7 days the last month)~Known allergy to Morphine or Ropivacaine~Congestive Heart Failure, New York Heart Association (NYHA) IIIB or worse~Chronic renal failure (S-creatinine increased)~Immunosuppression (more than 10 mg daily of Prednisolone or stronger medication)~No axillary exploration planned

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GA with RA (Type: ACTIVE_COMPARATOR): Regional Anesthesia and General Anesthesia.
- GA without RA (Type: ACTIVE_COMPARATOR): Only General Anesthesia (without a supplemental Regional Anesthesia).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (diagnosed clinically) for at least 12 months~* Currently treated with premixed human insulin 50 BID for at least 3 months prior to screening visit (Visit 1)~* Currently treated with unchanged total daily dose of at least 1500 mg metformin or maximum tolerated dose at least 1000 mg/day metformin for at least 2 months prior to screening visit~* Glycosylated haemoglobin (HbA1c) 7.0% and 9.0% (both inclusive) (central laboratory)~Exclusion Criteria:~* Treatment with any insulin secretagogue, alfa-glucosidase inhibitors, thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors and Glucagon-like peptide-1 (GLP-1) receptor agonists within the last 3 months prior to screening~* Previous use of any insulin other than premixed human insulin 50 BID within 3 months prior to Visit 1~* Previous use of insulin intensification treatment (premixed insulin thrice daily, basal bolus regimen, and continuous subcutaneous insulin infusion (CSII)) for more than 14 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment sequence 1 (Group A) (Type: EXPERIMENTAL): Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)
- Treatment sequence 2 (Group B) (Type: EXPERIMENTAL): Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Submission of a signed and dated informed consent form (guardian). Declared willingness to comply with all study procedures and accessibility during the study.~Children from 6 to 18 years old. Patients with PCR-confirmed COVID-19 with mild/moderate disease. U07.1. Ability to take oral medications and willingness to adhere to the regimen.~Exclusion Criteria:~Severe form of COVID-19. U07.1. Treatment with another investigational drug. Individual intolerance to the drug. The occurrence of any allergic reactions. Weighting of the general well-being of the patient and the transition to a severe form of the disease.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Target group (Type: EXPERIMENTAL): 201 children 6-18 years old with mild to moderate COVID-19, who were taking Rutan.
- control group (Type: OTHER): 100 children 6-18 years old with mild to moderate COVID-19, who were not taking Rutan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible for inclusion into the study, a patient must meet the following criteria:~* Has end-stage renal disease (ESRD) and has been on hemodialysis 3 times per week for at least 3 months prior to the start of screening;~* Has at least 2 single-pool Kt/V measurements ≥1.2, or at least 2 urea reduction ratio measurements ≥65%, or 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65% on different dialysis days during the 3 months period prior to screening;~* Prior to Treatment:~  * Has completed at least 3 Worst Itching Intensity NRS questionnaires from the start of the Run-in Period up to and including the pre-dose assessment on Day 1;~Key Exclusion Criteria:~A patient will be excluded from the study if any of the following criteria are met:~* Known noncompliance with dialysis treatment that in the opinion of the investigator would impede completion or validity of the study;~* Scheduled to receive a kidney transplant during the study;~* New or change of treatment received for itch including antihistamines and corticosteroids (oral, IV, or topical) within 14 days prior to screening;~* New or change of prescription for opioids, gabapentin, or pregabalin within 14 days prior to screening;~* Received another investigational drug within 30 days or five half-lives (whichever is longer) prior to the start of dosing or is planning to participate in another interventional clinical study while enrolled in this study;~* Has pruritus only during the dialysis session (by patient report);~* Is receiving ongoing ultraviolet B treatment and/or anticipates receiving such treatment during the study;~* Participated in a previous clinical study with CR845.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CR845 0.5mcg/kg (Type: EXPERIMENTAL): IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Diagnosis of RA according to the ACR-Criteria.~* Eligible for treatment with etanercept according to Summary of Product Characteristics (SmPC), and applicable local guidelines.~* Willing and able to self-inject etanercept.~Exclusion:~* Prior experience of biologics and anti-TNF treatment for their RA including etanercept.~* Sepsis or risk of sepsis.~* Current or recent infections, including chronic or localized.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enbrel 50 mg Prefilled Syringe (Type: EXPERIMENTAL): Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
- Enbrel 50 mg Autoinjector (Type: EXPERIMENTAL): Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete